Krahenbuhl J L, Sharma S D, Ferraresi R W, Remington J S
Infect Immun. 1981 Feb;31(2):716-22. doi: 10.1128/iai.31.2.716-722.1981.
Studies were carried out to determine whether treatment of mice with the synthetic adjuvant muramyl dipeptide afforded any resistance to infection with the obligate intracellular protozoan Toxoplasma gondii. Marked resistance to lethal challenge infection was observed in CBA but not C57BL/6 mice pretreated with muramyl dipeptide. In CBA mice, a single muramyl dipeptide treatment administered 14, 7, or 4 days before Toxoplasma challenge did not afford protection, whereas mice treated at -1 day were highly resistant. Additional studies carried out to investigate the mechanisms underlying the enhanced resistance to Toxoplasma in muramyl dipeptide-treated mice failed to reveal either enhanced cytolytic antibodies to the parasite or evidence that peritoneal macrophages from treated mice were activated as determined in vitro by their microbicidal capacity for Toxoplasma or cytotoxic capacity for tumor target cells.
开展了多项研究，以确定用合成佐剂胞壁酰二肽处理小鼠是否能使其对专性细胞内原生动物刚地弓形虫的感染产生任何抗性。在用胞壁酰二肽预处理的CBA小鼠中观察到对致死性攻击感染有显著抗性，但C57BL/6小鼠中未观察到。在CBA小鼠中，在弓形虫攻击前14天、7天或4天进行单次胞壁酰二肽处理未提供保护作用，而在攻击前1天处理的小鼠具有高度抗性。为研究胞壁酰二肽处理的小鼠对弓形虫抗性增强的潜在机制而开展的其他研究，未能揭示对该寄生虫的溶细胞抗体增强，也未发现证据表明处理过的小鼠的腹腔巨噬细胞通过其对弓形虫的杀菌能力或对肿瘤靶细胞的细胞毒性能力在体外测定时被激活。
